Dr. Fass has 35 years of senior pharmaceutical management experience. He retired from Savient Pharmaceuticals (SVNT; formerly Bio-Technology General Corp) after a 21 year tenure in which he served as CEO and Chairman from 1997-2004; President and CEO from 1984-1997; and COO from 1983-1984. Savient develops and commercializes specialty pharmaceuticals, some of which are genetically engineered. Under Dr. Fass’ leadership, Savient achieved revenues in excess of $125 million in 2004. From 1980-1983, Dr. Fass was Vice President and General manager of Wampole Laboratories, a division of Carter Wallace focusing on diagnostics of infectious diseases, immune-related disorders and reproduction. From 1969-1980, he held a numebr of marketing, sales and senior management positions at Pfizer, Inc. in both pharmaceuticals and diagnostics. In addition to being a Director of Cornerstone Pharmaceuticals, Inc., Dr. Fass has served as Director of Nanovirbronix since 2005. From 2005 to 2011, Dr. Fass served as Director of Novelos Therapeutics, Inc. He received a BS degree in biology and chemistry from Yeshiva College and a doctoral degree in developmental biology/biochemistry from the Massachusetts Institute of Technology.

slider bt care differently

slider bt discovery

500 characters left
nysehome
videohome
videobutton

Know the Science behind

AEMD Platform
Read More >>
Slide item 1

Another Breakthrough
A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Read More >>
Slide item 2

People behind the Success

Our Team
Read More >>
Slide item 3
announcement1
announcement2
announcement3